Pharma Pulse
search-icon

Tag: GAD treatment

Generalized Anxiety Disorder: Choosing Between SSRIs, Benzodiazepines, and CBT

Generalized Anxiety Disorder: Choosing Between SSRIs, Benzodiazepines, and CBT

Posted On May 8, 2026 0

Explore the pros and cons of SSRIs, benzodiazepines, and CBT for Generalized Anxiety Disorder. Learn why combination therapy often yields the best long-term results.

MOST POPULAR

Eczema & Tattoos: Safety Tips, Aftercare & What to Avoid

Eczema & Tattoos: Safety Tips, Aftercare & What to Avoid

Posted On October 15, 2025
Adjusting Medication Dose: Finding Your Optimal Balance of Benefits and Risks

Adjusting Medication Dose: Finding Your Optimal Balance of Benefits and Risks

Posted On January 28, 2026
IBD Biologics Explained: Anti-TNF, Anti-Integrin, and IL-12/23 Inhibitors for Crohn's and Colitis

IBD Biologics Explained: Anti-TNF, Anti-Integrin, and IL-12/23 Inhibitors for Crohn's and Colitis

Posted On January 5, 2026
Dry Eye Relief Guide: Medications, Lubricants, and Humidifiers

Dry Eye Relief Guide: Medications, Lubricants, and Humidifiers

Posted On July 3, 2026
Antidepressants: Types and Safety Profiles for Patients

Antidepressants: Types and Safety Profiles for Patients

Posted On December 18, 2025

Categories

  • Health (214)
  • Health Economics (18)

ARCHIVES

  • September 2026 (2)
  • August 2026 (12)
  • July 2026 (15)
  • June 2026 (12)
  • May 2026 (13)
  • April 2026 (7)
  • March 2026 (11)
  • February 2026 (11)
  • January 2026 (26)
  • December 2025 (29)
  • November 2025 (18)
  • October 2025 (30)
Pharma Pulse

Menu

  • About Pharma Pulse Weekly
  • Terms of Service
  • Privacy Policy
  • GDPR Compliance
  • Contact Us

Recent Posts

Eczema & Tattoos: Safety Tips, Aftercare & What to Avoid

Eczema & Tattoos: Safety Tips, Aftercare & What to Avoid

Posted On October 15, 2025
Adjusting Medication Dose: Finding Your Optimal Balance of Benefits and Risks

Adjusting Medication Dose: Finding Your Optimal Balance of Benefits and Risks

Posted On January 28, 2026
© 2026. All rights reserved.